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Mouse peritoneal macrophages activated for tumor cytotoxicity by any of
several in vivo or in vitro treatments released a soluble cytotoxin into culture
fluids only after exposure to small amounts of bacterial lipopolysaccharides. This
cytotoxic factor was physicochemically similar to the cytotoxic factor (tumor
necrosis factor) in sera of BCG-infected mice injected with lipopolysaccharide. A
rabbit antiserum against partially purified serum cytotoxic factor also inhibited
the activity of macrophage-derived cytotoxic factor. Of special interest was the
observation that rabbit anti-cytotoxic factor inhibited the cytotoxic activity of
macrophages both in the presence and in the absence of exogenously added
lipopolysaccharide. Inhibition was not complete but was consistent in all experi-
ments. Thus, cytotoxic factor was implicated as a possible effector molecule in
the nonspecific tumoricidal activity of activated macrophages.
The tumor necrotic effects of bacterial lipo-
polysaccharides (LPS) have been known for sev-
eral decades (2, 23). Recent findings by Carswell
et al. showed that this tumor necrosis activity is
mediated by a factor found in sera of LPS-
treated tumor-bearing animals (1). This factor
was also found in sera of BCG-infected mice
hours after LPS injection (BCG-LPS serum) (1).
That the serum factor also has cytotoxic activity
against tumor cells in vitro (but not against
normal embryo cells) provides a relatively sim-
ple and quantitative assay (1, 5, 8, 12, 20).
We have previously shown that a cytotoxic
factor (CF) physicochemically similar to that
found in BCG-LPS sera can be detected in cul-
tures of LPS-treated macrophages from BCG-
infected mice (9, 10). This observation suggested
that CF may contribute to the cytotoxic activity
of activated macrophages (9).
We have explored this possibility in this report
by using the immunoglobulin G (IgG) fraction
from a rabbit antiserum raised against serum-
derived CF to define a possible role for this
molecule in nonspecific macrophage-mediated
tumor cytotoxicity.
MATERIALS AND METHODS
Mice. Male and female C3H/HeN and C57BL/6N
mice, 6 to 12 weeks of age, were obtained from the
Division of Research Services, National Institutes of
Health.
LPS. LPS from Escherichia coli K235 was prepared
by the phenol-water extraction method of McIntire et
al. (13).
Lymphokine supernatant. C3H/HeN mice were
immunized intradermally with 5 x 106 viable Myco-
bacterium bovis, strain BCG (Phipps substrain, TMC
1029, Trudeau Mycobacterial Collection, Saranac
Lake, N.Y.) (22). Animals were sacrificed 3 to 6 weeks
after BCG immunization. Spleens were aseptically re-
moved and passed through no. 50 mesh stainless-steel
sieves into tissue culture medium (RPMI 1640 with
antibiotics; GIBCO Laboratories, Grand Island, N.Y.).
Single-cell suspensions, obtained by serial aspirations
through 19- and 23-gauge needles, were treated with
tris(hydroxymethyl)aminomethane-buffered NH4Cl
solution to lyse erythrocytes. Spleen cells were centri-
fuged at 250 x g for 10 min at 4°C and suspended to
a concentration of 5 x 106 viable cells/ml in medium
with 5% heat-inactivated fetal calf serum (GIBCO).
Twenty-milliliter portions of the spleen cell suspension
with 50 to 100ltg of purified protein derivative (Con-
nought Medical Research Laboratories, Toronto, Can-
ada) per ml were incubated in upright 75-cm2 plastic
tissue culture flasks (no. 3023; Falcon Plastics, Oxnard,
Calif.) for 48 to 60 h at 37°C. Supernatant fluids were
pooled, centrifuged at 450 x g for 15 min at 40C, and
stored at -20°C until used.
Preparation of cytotoxic serum. Mice were in-jected intravenously with 2 x 106 viable BCG and
injected intravenously 14 days later with 10,ug of LPS.
Two hours after LPS injection, animals were exsan-
guinated, and the serum (BCG-LPS serum) was pre-
pared (8). Control serum was obtained from LPS-
injected normal mice in a similar manner. All sera
were stored at -20°C until used.
Antisera. Female rabbits (New Zealand white)
156
 at R
EG
ENSBURG
 on July 15, 2009 
iai.asm
.org
D
ow
nloaded from
 
CYTOTOXIC FACTOR AND MACROPHAGE CYTOTOXICITY 157
were obtained from the Division of Research Services,
National Institutes of Health. Animals were immu-
nized with BCG-LPS serum-derived tumor CF par-
tially purified by Sephacryl S200 and diethylamino-
ethyl-Sephacel (Pharmacia Fine Chemicals, Inc., Pis-
cataway, N.J.) chromatography or with an equivalent
fraction from control serum. Rabbits were injected
subcutaneously in complete Freund adjuvant as de-
scribed (8, 9). Each immunizing preparation contained
about 25 mg of protein per injection. The animals were
boosted with the same antigen preparations subcuta-
neously in complete Freund adjuvant twice at 3 and 8
weeks and again at periodic intervals without Freund
adjuvant. Rabbits were bled from the ear artery, and
serum was prepared. All antisera were heat inactivated
(30 min at 56°C), and the proteins were precipitated
with 50% saturated ammonium sulfate. Precipitates
were dissolved and extensively dialyzed against phos-
phate-buffered saline (PBS). Heat-inactivated serum
was applied on protein A-Sepharose CL-4B (Phar-
macia) at pH 7, and IgG was eluted with glycine buffer
at pH 3. This IgG fraction was extensively dialyzed
against Dulbecco minimal essential medium (DMEM).
Normal rabbit IgG was obtained from Cappel Labo-
ratories, Inc., Downingtown, Pa.
Peritoneal cells. Mice were treated intraperito-
neally (i.p.) 1 day previously with 1 ml of PBS or 7
days previously with: (i) 2 x 106 viable BCG; (ii) 500
ag of pyran copolymer (National Cancer Institute,
Bethesda, Md.); (iii) 1.4 mg of killed Corynebacterium
parvum (Wellcome Research Laboratories, Becken-
ham, England); (iv) 2% starch suspension (Connought
Medical Research Laboratories); or (v) 1:1,000 suspen-
sion of latex beads (1-,um polystyrene beads; Dow
Chemical Co., Midland, Mich.) in 0.5 ml of PBS each.
Peritoneal exudate cells (PEC) were collected after i.p.
injection of 8 to 10 ml of DMEM as described (21).
This medium contained 2 g of NaHCO3 and 4.5 g of
glucose per liter, 10% fetal calf serum, and 50 ,ug of
gentamicin per ml. Peritoneal fluid was withdrawn
through the anterior wall through a 19-gauge needle.
Fluids from 3 to 10 mice were pooled, a sample was
taken for differential and total cell counts, and the
remainder was centrifuged in polypropylene tubes (no.
2074; Falcon Plastics) at 250 x g for 10 min at 4°C.
Differential counts were made on Wright-stained cell
smears prepared by cytocentrifugation (Cytospin cen-
trifuge; Shandon Southern Instruments, Camberley,
England). Washed PEC suspensions from each pool of
mice were adjusted to equal macrophage concentra-
tions in medium used for cell collection. Macrophages
were exposed to dilutions of lymphokine supernatants
as adherent PEC for 6 h at 37°C in 5% C02 in moist
air.
CF assay. Tumor cells (mouse L929, American
Type Culture Collection, Rockville, Md., unless indi-
cated otherwise) at 4 x 103 cells per 6.4-mm culture
well (Costar 96, Cambridge, Mass.) were labeled in 0.1
ml of Eagle minimal essential medium (EMEM) with
25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesul-
fonic acid (HEPES) buffer, 5% heat-inactivated fetal
calf serum, and 0.5 MuCi of [methyl-3H]thymidine per
ml ([3H]TdR; specific activity, 6.7 Ci/mmol; New Eng-
land Nuclear Corp., Boston, Mass.) for 18 to 24 h at
37°C in 5% CO2 in moist air (7). Tumor cell monolayers
were washed twice after labeling and incubated with
dilutions of cytotoxic samples in 0.2 ml of DMEM.
After 48 h, labeled tumor cell monolayers lysed with
0.5% sodium dodecyl sulfate (SDS) in water were used
to estimate total incorporated [3H]TdR. Cytotoxicity
was estimated by measuring release of [3H]TdR from
prelabeled tumor cells in duplicate cultures and ex-
pressed as mean counts per minute + standard error
of the mean (SEM) or as percentage of SDS total
counts.
Macrophage cytotoxicity assay. A modified pro-
tocol of the cytotoxicity assay described by Meltzer et
al. (15) was used. Tumor 1023 was induced in a C3H/
HeNicr male mouse with pellets of 1% 3-methylchol-
anthrene in paraffin. Target cell lines were established
from enzyme-digested tumor fragments and were
maintained in culture with EMEM supplemented with
10% fetal calf serum. [3H]TdR-prelabeled tumor cells
were obtained from washed and trypsin-digested
monolayers (2 x 106 to 3 x 106 viable cells/75-cm2
culture flask in 20 ml of EMEM with 25 mM HEPES
buffer, 5% fetal calf serum, and 1 M,Ci of [3H]TdR per
ml for 18 to 24 h at 370C in 5% C02 in moist air). Six
thousand tumor cells were added to 6.4-mm culture
wells (Costar 96) with in vivo- or in vitro-activated
adherent PEC in a total volume of 0.2 ml of DMEM.
After 48 h, labeled tumor cell monolayers lysed with
0.5% SDS in water were used to estimate total incor-
porated counts. Cytotoxicity was estimated by mea-
surement of release of [3H]TdR from prelabeled tumor
cells in duplicate cultures and expressed as mean
counts per minute ± SEM or percentage of SDS total
counts.
RESULTS
Correlation between macrophage tumor-
icidal activity and release of CF. A soluble
CF physicochemically similar to that found in
BCG-LPS sera is detected in culture fluids of
LPS-treated macrophages from BCG-infected
animals (9, 10). To determine whether CF plays
a role in the nonspecific tumoricidal activity of
activated macrophages in vitro, we attempted to
correlate levels ofmacrophage tumoricidal activ-
ity with release of CF into culture fluids (Table
1). Macrophages from mice treated i.p. with
viable BCG, killed C. parvum, or pyran copoly-
mer were strongly cytotoxic to tumor cells in
vitro; cells from mice treated with PBS, starch,
or latex beads had little or no cytotoxic activity.
Levels of CF released by any of these cytotoxic
or noncytotoxic macrophages, however, were
negligible. These observations confirm those in
many previous reports which failed to detect
soluble cytotoxins in cultures of activated mac-
rophages (see reference 6 for review).
The pattern of CF release by macrophage
cultures incubated with small amounts of LPS,
however, was entirely different from that de-
scribed above. Cultures of activated macro-
phages from three different sources (BCG-, C.
VOL. 33, 1981
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TABLE 1. Correlation between macrophage tumoricidal activity and release of cytotoxic factora
Macrophages from mice treated Macrophage tumoricidal Release of CFb
with: activity
-LPS +LPS
BCG 2,240 ± 130 (26) 470 ± 20 (11) 1,410 ± 60 (33)
Pyran 2,380 ± 250 (27) 640 ± 10 (15) 1,600 ± 110 (38)
C. parvum 2,020 ± 130 (23) 560 ± 20 (13) 1,640 ± 80 (39)
PBS 770± 70 (9) 340 ± 30 (8) 480 ± 60 (11)
Starch 620 ± 20 (7) 360 ± 80 (8) 360 ± 60 (8)
Latex 790± 10 (9) 340 ± 40 (8) 400 ± 60 (9)
No macrophages 680 ± 70 (8) 220 ± 70 (5)
SDS total counts 8,740 ± 700 (100) 4,250 ± 170 (100)
a Adherent PEC from mice treated i.p. with 2 x 106 viable BCG, 500 ,ug of pyran, 1.4 mg of C. parvum, 2%
starch in water, or latex beads 7 days previously or with PBS 1 day previously were incubated with [3H]TdR-
prelabeled tumor cells. Cytotoxicity (released [3H]TdR) was estimated at 48 h and expressed as mean counts
per minute ± SEM for duplicate cultures and as percentage of SDS total counts (in parentheses).
b For release of CF, the cytotoxic activity of 2-h supernatants from 10' adherent PEC was tested on [3H]TdR-
prelabeled L929 cells. Cytotoxicity (released [3H]TdR) was estimated at 48 h and expressed as mean counts per
minute ± SEM for duplicate cultures and as percentage of SDS total counts (in parentheses).
parvum-, or pyran-treated mice) incubated with
10 ng ofLPS per ml released significant levels of
CF. LPS alone (data not shown) or culture fluids
from LPS-treated inflammatory macrophages
had little or no cytotoxic activity (Table 1).
Even though detectable levels of CF were
evident only in culture fluids of activated mac-
rophages treated with an extraordinary stimulus
such as LPS, CF could still contribute to the
cytotoxic effects of these cells in the absence of
LPS. For example, CF bound to macrophages or
released only in the macrophage-tumor cell mi-
croenvironment would not be detected in culture
fluids. To examine this alternative, we at-
tempted to inhibit CF activity with a partially
purified and specific rabbit antiserum.
Inhibition of the cytotoxic activity in
BCG-LPS sera by rabbit antiserum against
serum-derived CF. CF in sera of BCG-infected
mice treated intravenously with LPS was par-
tially purified by ammonium sulfate precipita-
tion, diethylaminoethyl ion exchange, and
Sephacryl S200 chromatography as previously
described (8). Sera of normal mice treated with
LPS (control sera) were fractionated by an iden-
tical protocol. Rabbits were immunized with
purified CF or control sera and bled periodically.
The ammonium sulfate precipitate of serum
from rabbits immunized with CF inhibited the
cytotoxic activity in BCG-LPS sera: 50% inhibi-
tion was evident at a 1:640 dilution of antiserum;
inhibition was complete at 1:160 (Fig. 1). In
contrast, control serum even at the highest con-
centration (1:40) effected only a slight inhibition
of cytotoxic activity.
The inhibitory activity of rabbit anti-CF was
isolated in the IgG fraction (Table 2). IgG from
rabbit anti-CF purified by elution from protein
A-Sepharose strongly inhibited the cytotoxic ac-
40
20-
Anti-CF serum
1/160 1/80 1/40
SERUM DILUTION
FIG. 1. Inhibition of the cytotoxic activity in BCG-
LPS sera by rabbit attisera directed against serum-
derived CF. [3H]TdR-labeled L929 cells were incu-
bated with 1:1,000-diluted BCG-LPS serum (-) or
medium (---). Dilutions of ammonium sulfate precip-
itates of heat-inactivated anti-CF (0) or control se-
rum (0) were added. Cytotoxicity was estimated by
measurement of [3H]TdR release at 48 h and ex-
pressed as percentage of SDS total counts (total in-
corporated counts per minute = 3 x 103).
tivity of BCG-LPS sera on both L929 and 1023
tumor target cells; IgG from control sera had
little or no effect. That inhibition of cytotoxic
activity in BCG-LPS sera by IgG from rabbit
anti-CF was due to specific interactions with CF
in BCG-LPS sera and not to "nonspecific" pro-
tective effects on target cells was demonstrated
by the following experiment. Protein A-Sepha-
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CYTOTOXIC FACTOR AND MACROPHAGE CYTOTOXICITY 159
rose columns were exposed to equal concentra-
tions of IgG from anti-CF and control sera.
When BCG-LPS serum was passed over the
anti-CF column, all cytotoxic activity was re-
tained. In contrast, the titer of cytotoxic activity
in BCG-LPS serum was unchanged after passage
over the control serum column (Table 3).
Effect of rabbit anti-CF on the tumorici-
dal activity ofactivated macrophages. Mac-
rophages activated in vivo by the effects ofBCG
infection or activated in vitro by lymphokines
were cultured with tumor target cells in the
presence of IgG from sera of immunized (anti-
CF), control (control sera), and untreated rab-
bits (Fig. 2). Anti-CF exerted a significant inhib-
itory effect on macrophage-mediated cytotoxic-
ity with both BCG- and lymphokine-activated
cells. Inhibition was most evident at the lower
effector/target cell ratios. IgG from sera of un-
treated rabbits had no effect on macrophage
tumoricidal activity. In contrast, IgG from sera
of control rabbits (animals immunized with sera
from normal mice injected with LPS) actually
enhanced tumor cytotoxicity. Since both target
cells and mouse serum were ofC3H/HeN origin,
enhancing activity in control serum could have
been mediated by rabbit anti-C3H/HeN anti-
bodies not present in sera of untreated rabbits.
In fact, absorption of all rabbit sera with 1023
target cells reduced this enhancement without
affecting the inhibitory effects of anti-CF (Fig.
3).
The inhibitory effects of anti-CF on tumor
cytotoxicity by activated macrophages was in-
dependent of mouse strain and activation stim-
ulus (Table 4). Effects of anti-CF were, however,
dependent upon the effector/target cell ratio
and the amount of anti-CF added during the
cytotoxicity assay. Inhibition of macrophage tu-
moricidal activity was not evident at effector/
target cell ratios greater than or equal to 15:1 to
20:1 or with less than 0.25 ,ug of anti-CF IgG per
ml (data not shown). This latter effect was not
due to loss by absorption or destruction of anti-
body activity during the 48-h cytotoxicity assay.
The titer of anti-CF in fluids of BCG-activated
macrophage-tumor cell cultures (at 20:1 and 7:1
effector/target cell ratios) remained unchanged
through 48 h.
Detectable levels of CF in fluids of activated
macrophage cultures are found only after expo-
sure of cells to small amounts of LPS. CF is
released within 2 h of LPS treatment. If LPS-
treated macrophages are washed after this 2-h
interval, the cells remain cytotoxic but CF can-
not be detected in culture fluids again through
48 h (8). It is possible that anti-CF inhibits only
the initial, LPS-dependent event. Later cyto-
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160 MANNEL, FALK, AND MELTZER
TABLE 3. Absorption of cytotoxic activity from BCG-LPS sera by rabbit anti-CF bound to protein A-
Sepharose
Cytotoxicity
Eluate'
Ani-F gGProtein A coated with BfeEluateaAnti-CF IgG control IgG Buffer
1:4,000 590 ± 60 (13) 770 ± 190 (17) 790 ± 60 (18)
1:2,000 590 ± 60 (13) 920 ± 160 (21) 910 ± 130 (20)
1:1,000 650 ± 60 (14) 1,240 ± 210 (28) 1,210 ± 40 (27)
1:500 610 ± 50 (14) 1,580 ± 50 (35) 1,680 ± 130 (37)
Spontaneous release 600 ± 40 (13)
SDS total counts 4,480 ± 240 (100)
a One milliliter samples of protein A-Sepharose CL-4B were each coated with buffer, 5 mg of anti-CF IgG, or
5 mg of control IgG. Samples of 10 p1 of BCG-LPS serum were applied to the columns, and 5 ml of the eluate
was collected. [3H]TdR-labeled L929 celis were incubated with different dilutions of the eluates. Cytotoxicity
was estimated by [3H]TdR release at 48 h and expressed as mean counts per minute ± SEM for duplicate
cultures and as percentage of SDS total counts (in parentheses). More than 50% of the cytotoxic activity from
BCG-LPS serum applied was recovered from the uncoated column (buffer).
Contro IgG
p Anti-~xCF Ig
PBS-Macrages
+ LWr#vkines
BCG-Macophages
5:1 7:1
EFFECTOR: TARGET
FIG. 2. Inhibition of macrophage tumc
tivity by IgG from rabbit anti-CF. Adh
from mice treated i.p. with PBS 1 day prei
treated in vitro with lymphokines (1:5 dili
dium) for 6 h or adherent PEC from mice
with 2 x 106 viable BCG 7 days previ
incubated at different effector/target
[3H]TdR-labeled tumor cells. The cells we
in medium (O), rabbit IgG (U), anti-CF
control IgG (-). Final IgG concentrationl
ml. Cytotoxicity was estimated by [3H]Td)
toxic mechanisms may be unrelated to this early
event and thus may not be inhibited by anti-CF.
;4<To test this possibility, we examined effects of
anti-CF on tumor cytotoxicity by BCG-activated
macrophages cultured with and without LPS for
2 h. All cultures were then washed and incubated
with anti-CF and target cells (Fig. 4). Anti-CF
inhibited the cytotoxic activity of both LPS-
treated and nontreated BCG-activated macro-
IG phages. The degrees of inhibition were compa-
rable.
It is important to note that the measurement
of macrophage-mediated tumor cytotoxicity by
release of [3H]TdR used in these studies under-
estimates the extent of macrophage-tumor cell
interaction. Macrophage-mediated cytostatic ef-
fects are not measured by this assay. Moreover,
A4 dead tumor cells that have not yet autolyzed
and released nuclear [3H]TdR by 48 h are like-
wise not measured (15). Culture morphology
(Fig. 5) demonstrates the striking effects of anti-
CF on activated macrophage-tumor cell inter-
actions. Cultures incubated in medium alone
showed the strong cytopathic effects of activated
macrophages on tumor cells (bottom). The cell
density did not increase over 48 h. Morphology
of cultures incubated with IgG from control or
-.'----- normal rabbit sera was comparable to that of
9:1 cultures incubated in medium alone (middle). In
contrast, cell density of cultures in the presence
)ricidal ac- of anti-CF was very high (top) and similar to the
erent PEC cell density obtained when noncytotoxic resident
viously and macrophages 'were cultured with tumor cells.
.uted in me- Since only tumor cells are able to grow underinfected lv.P these conditions, increased cell density can be
tzosy Werith attributed only to tumor cell growth.
ere cultured
IgG (0), or
was 0.5 mgl
R release at
48 h and expressed aspercentage ofSDS total counts
(total incorporated counts per minute = 6 x 103;
spontaneous release = 7%).
40k
201-
0
aR40
20 -
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DISCUSSION
Data presented in this report demonstrate for
a variety of in vivo and in vitro treatments that
macrophages activated for nonspecific tumor cy-
totoxicity are also able to release soluble cyto-
toxic factor after exposure to small amounts
(nanograms) of LPS. Activation in vivo or in
vitro, however, was not sufficient for CF release.
60 r
-
4Contrc IgG
/ Medium
Absorbed
/ W control IgG
,/ 1
Anti-CF IgG
Absbed
anti-CF IgG
Over a broad range of experimental conditions,
LPS was always necessary. Moreover, after the
initial LPS-induced release ofCF from activated
macrophages, further release ofCF with or with-
out LPS was not evident (8).
These observations suggest that release of CF
from activated macrophages is yet another ex-
ample ofmacrophage effector function regulated
by two stages: cells must be primed by one
stimulus to enter into an inactive but receptive
stage in which they can then respond or be
30 F
20
I-
10
3:1 5:1 7:1 9:1
EFFECTOR: TARGET
FIG. 3. Inhibition of macrophage tumoricidal ac-
tivity by anti-CF from rabbit sera absorbed with 1023
fibrosarcoma cells. Two milliliters of IgG solutions
(1 mg/ml) was absorbed three times with 25 x 10i
1023 cells each for 30 min at 0°C. Adherent PECfrom
mice treated i.p. with 2 x 106 viable BCG 7 days
previously were incubated at different effector/target
ratios with [3H]TdR-labeled tumor cells. The cells
were cultured in medium (0), unabsorbed (---) or
absorbed (-) anti-CF IgG (0), or control IgG (0).
Final IgG concentration was 0.5 mg/ml. Cytotoxicity
was estimated by [3H]TdR release at 48 h and ex-
pressed as percentage ofSDS total counts (total in-
corporated counts per minute = 3.5 x 103; sponta-
neous release = 14%).
0' l
[=~----
5:1 7:1
EFFECTOR: TARGET
9:1
FIG. 4. Anti-CF inhibition of macrophage tumori-
cidal activity after treatment with LPS. Adherent
PEC of mice treated i.p. with 2 x 106 viable BCG 7
days previously were incubated in medium (-) or in
medium containing 10 ng ofLPSper ml (---) for 2 h.
The cells were washed three times and cultured with
[3H]TdR-labeled tumor cells in medium (P) or ab-
sorbed anti-CFIgG (0). Final IgG concentration was
0.5 mg/ml. Cytotoxicity was estimated by [3H]TdR
release at 48 h and expressed as percentage of SDS
total counts (total incorporated counts per minute =
3 x 103; spontaneous release = 5%).
TABLE 4. Inhibition ofmacrophage cytotoxicity by IgG against serum-derived CF'
Cytotouicity
Mouse strain Stimulus
Anti-CF IgG Medium
C3H/HeN BCG 480 ± 50 (40) 1,060 ± 40 (89)
Pyran 560 ± 30 (47) 1,030± 90 (86)
C. parvum 770 ± 30 (64) 1,070 ± 80 (90)
C57BL/6N BCG 470 ± 40 (40) 780 ± 100 (65)
Spontaneous release 170 ± 10 (14)
SDS total counts 1,200 ± 90 (100)
'Adherent PEC from mice treated i.p. with 2 x 106 viable BCG, 500 pg of pyran, or 1.4 mg of C. parvum 7
days previously were incubated with [3H]TdR-labeled tumor cells at a 10:1 effector/target ratio. Cytotoxicity
was estimated by [3H]TdR release at 48 h and expressed as mean counts per minute ± SEM for duplicate
cultures and as percentage of SDS total counts (in parentheses).
40 k
0
0
20F-
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CYTOTOXIC FACTOR AND MACROPHAGE CYTOTOXICITY 163
triggered by another stimulus for full functional
activity. Other seemingly unrelated examples of
this two-stage regulation include: secretion and
release of plasminogen activator (3), of prosta-
glandin E2 (16), and of lymphocyte-activating
factor (IL1; 17); elicitation of the H202 burst (18,
19); and C3b receptor-mediated phagocytosis (4).
The exact role of CF in nonspecific tumorici-
dal activity of activated macrophages is not yet
defined. Data presented in this report show that
the cytotoxic activity of activated macrophages
from a variety of sources can be partially but
reproducibly inhibited by a purified rabbit anti-
CF. Inhibition by anti-CF was effected even with
activated macrophages that released no detect-
able CF in culture and also with activated mac-
rophages that had previously released CF in a
response to an LPS trigger and were incapable
of further release. The inhibitory effect of anti-
CF was not due to functional damage of the
macrophage effector cell: (i) antibody-mediated
cytotoxicity by BCG-activated macrophages for
51Cr-labeled TNP modified chicken erythrocytes
was unaffected by anti-CF (D. Mannel, unpub-
lished data); and (ii) activated macrophages in-
cubated with anti-CF for up to 2 h remained
cytotoxic after removal of antibody by washing.
In fact, we could not demonstrate binding of
anti-CF to the activated cytotoxic macrophage
by any of several techniques: the anti-CF titer
in fluids of activated macrophage cultures was
unchanged through 48 h even though the cyto-
toxic activity of these activated cells was
strongly inhibited. Moreover, use of fluorescein-
labeled anti-rabbit antibody to demonstrate
binding of rabbit anti-CF to cytotoxic cells or
direct attempts to show binding with iodinated
Fab fragments of anti-CF were unsuccessful
(Mannel, unpublished data). CF may be stored
within the macrophage and secreted or exposed
on the cell membrane only after LPS treatment
or perhaps after tumor cell contact.
Complete or near complete inhibition of mac-
rophage cytotoxic activity by anti-CF was evi-
dent only at low effector/target cell ratios. At
ratios greater or equal to 15:1 to 20:1, macro-
phage tumoricidal activity was unaffected even
by the highest concentration of antibody. Inhi-
bition was not complete at any level of cytotox-
icity (range, 33 to 89%) but was consistent in all
experiments. Cinemicrographic and microscopic
studies of activated macrophages and tumor
cells show that tumor cell destruction involves
close contact between effector and target cells
(11, 14). In fact, recent studies suggest that bind-
ing of tumor cells to macrophages may be a
prerequisite event for cytolysis (11). One could
assume that the failure to detect anti-CF inhi-
bition at high macrophage/tumor cell ratios re-
flects steric exclusion of the antibody from the
presumed site of killing, the area of contact
between macrophage and tumor cell. Alterna-
tively, cytotoxic mechanisms of nonspecifically
activated macrophages may vary with the mi-
croenvironment. CF may play a major role in
cytotoxicity at low cell densities, a hypothesis
consistent with the inhibitory effects of anti-CF.
Cytotoxicity at higher cell densities, however,
might be mediated by multiple and overlapping
mechanisms so that elimination of CF-mediated
events would be compensated.
In any event, the data presented in this report
strongly implicate CF as at least one of the
effector molecules in activated macrophage-me-
diated tumor cytotoxicity. The interesting find-
ings by Kull and Cuatrecasas that CF must be
internalized by the target cell to obtain cytolysis
(C. F. Kull, Jr., and P. Cuatrecasas, Fed. Proc.
39: 478, 1980) and the observations in this paper
suggest a series of future experiments that could
clarify the mechanisms of macrophage tumori-
cidal activity.
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